210 related articles for article (PubMed ID: 27029073)
21. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
Hamblett KJ; Kozlosky CJ; Siu S; Chang WS; Liu H; Foltz IN; Trueblood ES; Meininger D; Arora T; Twomey B; Vonderfecht SL; Chen Q; Hill JS; Fanslow WC
Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
[TBL] [Abstract][Full Text] [Related]
22. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
Pitter KL; Galbán CJ; Galbán S; Tehrani OS; Li F; Charles N; Bradbury MS; Becher OJ; Chenevert TL; Rehemtulla A; Ross BD; Holland EC; Hambardzumyan D
PLoS One; 2011 Jan; 6(1):e14545. PubMed ID: 21267448
[TBL] [Abstract][Full Text] [Related]
23. Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
Lee EJ; Sung JY; Koo KH; Park JB; Kim DH; Shim J; Lee CH; Park J; Kim YN
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256086
[TBL] [Abstract][Full Text] [Related]
24. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin inhibits the growth of glioblastoma.
Arcella A; Biagioni F; Antonietta Oliva M; Bucci D; Frati A; Esposito V; Cantore G; Giangaspero F; Fornai F
Brain Res; 2013 Feb; 1495():37-51. PubMed ID: 23261661
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Chakrabarti M; Ray SK
Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation.
Xia Q; Zhang H; Zhang P; Li Y; Xu M; Li X; Li X; Dong L
Oncogene; 2020 Sep; 39(36):5902-5915. PubMed ID: 32737433
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
30. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
31. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
[TBL] [Abstract][Full Text] [Related]
33. Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.
Su Z; Han S; Jin Q; Zhou N; Lu J; Shangguan F; Yu S; Liu Y; Wang L; Lu J; Li Q; Cai L; Wang C; Tian X; Chen L; Zheng W; Lu B
Cell Death Dis; 2021 Mar; 12(3):251. PubMed ID: 33674562
[TBL] [Abstract][Full Text] [Related]
34. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
35. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
[TBL] [Abstract][Full Text] [Related]
36. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
37. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
Qi Q; He K; Yoo MH; Chan CB; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H; Fu H; Tao H; Ramalingam SS; Sun SY; Mischel PS; Ye K
J Biol Chem; 2012 Feb; 287(9):6113-27. PubMed ID: 22215664
[TBL] [Abstract][Full Text] [Related]
38. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
39. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT
J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827
[TBL] [Abstract][Full Text] [Related]
40. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.
Lu CH; Wyszomierski SL; Tseng LM; Sun MH; Lan KH; Neal CL; Mills GB; Hortobagyi GN; Esteva FJ; Yu D
Clin Cancer Res; 2007 Oct; 13(19):5883-8. PubMed ID: 17908983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]